BackKintara Therapeutics Overview

Kintara Therapeutics Receivables

Track Kintara Therapeutics's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Kintara Therapeutics Receivables History

Loading

Kintara Therapeutics vs. peers: Receivables Comparison

Loading

Kintara Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kintara Therapeutics (KTRA) FAQ

The latest receivables for KTRA is $0 as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Kintara Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KTRA's receivables moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kintara Therapeutics's operating scale or balance-sheet position.

A receivables figure of $0 for KTRA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KTRA's receivables ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Kintara Therapeutics's receivables against similar Materials names. You can also browse sector and industry screens on Stockcircle for a broader set of Materials companies and their key multiples and fundamentals.